exRNAdisease

Entry Detail

---



General Information

Database ID: exR0275651 RNA Name: hsa-miR-491-5p RNA Type: miRNA Chromosome: chr9 Starnd: + Coordinate: Start Site(bp): 20716120 End Site(bp): 20716141 External Links: hsa-miR-491-5p

Disease Information

Disease Name: Advanced Adenoma Disease Category: Cancers MeSH ID: D000236 Type: Neoplasms/Neoplasms, Glandular and Epithelial Alias: Adenoma//Adenomas//Adenoma, Follicular//Adenomas, Follicular//Follicular Adenoma//Follicular Adenomas//Adenoma, Trabecular//Adenomas, Trabecular//Trabecular Adenoma//Trabecular Adenomas//Adenoma, Monomorphic//Adenomas, Monomorphic//Monomorphic Adenoma//Monomorphic Adenomas//Adenoma, Papillary//Adenomas, Papillary//Papillary Adenoma//Papillary Adenomas//Adenoma, Basal Cell//Adenomas, Basal Cell//Basal Cell Adenoma//Basal Cell Adenomas//Adenoma, Microcystic//Adenomas, Microcystic//Microcystic Adenoma//Microcystic Adenomas

Expression Detail

GEO ID: GSE25609 Description: Plasma microRNA profiling by microarray elucidates several candidate biomarkers for colorectal cancer screening Experimental Design: Cancer vs Control Case Disease Type: Advanced Adenoma Case Disease SubType: NA Case Sample: Advanced Adenoma Post surgery Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand IGFBP4 chr17 40443450 40457725 + SRF chr6 43171269 43181506 + CDR2L chr17 74987632 75005800 + CENPB chr20 3783851 3786740 - RBFOX2 chr22 35738736 36028824 - SPRED2 chr2 65310851 65432637 - PHB2 chr12 6965327 6970753 - PTPRU chr1 29236516 29326813 + PTBP3 chr9 112217716 112333667 - SLC6A6 chr3 14402576 14489349 + SNAI1 chr20 49982980 49988886 + NDST1 chr5 150485818 150558211 + PPP4C chr16 30075978 30085376 + LIMD2 chr17 63695888 63701172 - TTPAL chr20 44475874 44494603 + SAMD4B chr19 39342396 39385710 + QSOX2 chr9 136206333 136245812 - C19orf47 chr19 40319536 40348527 - ZNF574 chr19 42068477 42081552 + PDXP chr22 37658723 37666932 + MEF2D chr1 156463727 156500779 - TP53 chr17 7661779 7687550 - ATXN7L3 chr17 44191805 44200113 - CPSF7 chr11 61402641 61430031 - CD151 chr11 832887 839831 + DIRAS1 chr19 2714567 2721372 - COL4A2 chr13 110305812 110513209 + NOTCH2 chr1 119911553 120100779 - INTS2 chr17 61865367 61928016 - HDGF chr1 156742109 156766925 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000128 chr1 151139409 151139890 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC016876.2 chr17 7581964 7584086 - AC023509.1 chr12 53441741 53467528 + AC069281.2 chr7 100572232 100578700 - AL355987.2 chr9 136800366 136829466 + AL645608.6 chr1 904834 915976 + H19 chr11 1995176 2001470 - LINC01278 chrX 63222993 63561095 - MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + PCBP2-OT1 chr12 53464468 53465057 + VPS9D1-AS1 chr16 89711856 89718165 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE25609 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 826 Sample treatment protocol: Briefly, samples were centrifuged at 1,600×g for 10 min at 4 ºC to spin down blood cells, and plasma was transferred into new tubes, followed by further centrifugation at 16,000×g for 10 minutes at 4ºC to completely remove cellular components. RNA Extract protocol: NA RNA library preparation protocol: Biotinylated cDNA were prepared with the Illumina® TotalPrep™ RNA Amplification Kit (Ambion).

Reference

PMID: 23267864 Title: Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study Author: Gir¨¢ldez MD, Lozano JJ, Ram¨ªrez G, Hijona E, Bujanda L, Castells A, Gironella M Journal: Clin Gastroenterol Hepatol. 2013 Jun;11(6):681-8.e3. Description: We investigated whether plasma levels of miRNA can differentiate patients with CRC from healthy individuals. We also investigated whether plasma samples from patients with premalignant neoplastic lesions, such as advanced adenomas (AAs), also had a different expression pattern of miRNAs.